During the pandemic influenza A, a five-year-old boy was admitted to the hospital with the complaints of high fever, cough and sneezing. Influenza virus analysis from the nasopharyngeal discharge was positive for influenza A virus. The patient previously had an acute hemolytic attack after eating fava beans, and glucose-6-phosphate dehydrogenase (G6PD) deficiency was later established. As he ha...

BACKGROUND Oseltamivir is widely used as treatment for influenza virus A subtype H5N1 (hereafter, "H5N1") infection but, like any intervention, is not always effective. METHODS We used Avian Influenza Registry data from 10 countries to examine the risk of death in 215 patients with confirmed H5N1 infection who were treated with oseltamivir, according to viral clade, age, respiratory failure, ...

Synthesis of novel neuraminidase inhibitor -- carborane ester of oseltamivir carboxylic acid is described, and its physicochemical and spectral characteristics is provided. Surprisingly, carborane analog of oseltamivir is of an order of magnitude less active than its precursor, the corresponding ethyl ester, which is the active principle of pharmaceutical preparations used in influenza prophyla...

We reviewed information from a US pharmacy benefits manager database from 2004 through 2005 during periods with little influenza activity. We calculated rates of oseltamivir prescriptions to enrollees. Prescription rates increased significantly from 27.3/100,000 in 2004 to 134/100,000 in 2005 (p<0.05), which suggested that personal stockpiling of oseltamivir occurred.

With the threat of significant morbidity and mortality following an influenza pandemic, stockpiling of antiviral agents such as oseltamivir is recommended. Shelf-life extension was explored to maximize use of an existing stockpile. This analysis demonstrated that oseltamivir retains potency defined by United States Pharmacopeia acceptance criteria beyond the labeled expiration date.

To investigate the frequency of oseltamivir resistance in circulating strains of the 2009 influenza A(H1N1) pandemic virus in Scotland, 1,802 samples from 1,608 infected hospitalised patients were screened by the H275Y discriminatory RT-PCR. Among these, we identified 10 patients who developed the H275Y mutation. All of them were immunocompromised and were under treatment or had been treated pr...

Amino acid substitutions in influenza virus neuraminidase (NA) that cause resistance to inhibitors (NAI) generally result attenuation. However, viruses may acquire secondary the NA and hemagglutinin (HA) proteins can restore viral fitness. To assess which extent this happens, emergence of NAI – potentially compensatory was quantified immunocompetent individuals included Influenza Resistance Inf...

OBJECTIVE To describe the potential benefits and harms of oseltamivir by reviewing all clinical study reports (or similar document when no clinical study report exists) of randomised placebo controlled trials and regulatory comments ("regulatory information"). DESIGN Systematic review of regulatory information. DATA SOURCES Clinical study reports, trial registries, electronic databases, reg...